-The Hindu   Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in...

-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

One man’s fiscal problem is another man’s lifeline. Trigger happy bureaucrats and economists may love shooting down subsidies because it bloats the fiscal deficit and burdens the government but the simple fact is that in a one billion strong nation, in which nearly one in every three live below the poverty line, one needs an effective and efficient method through which privileged tax payers can support the poor. Last week, finance...

-The Hindu Food subsidies for poorest will help them cope: ADB A hike in the cost of food staples like rice and wheat could push tens of millions more people into extreme poverty in the South Asian region including India, says an Asian Development Bank (ADB) report. The Manila-based lending agency, in its report “Food Price Escalation in South Asia – A Serious and Growing Concern” released on Monday, however, said that food...

India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...